Financial Performance - In the first half of 2025, the company reported operating revenue of 505 million yuan, a decrease of 8.63% year-on-year [1][2] - The net profit attributable to shareholders was -13.38 million yuan, representing a decline of 188.64% compared to the same period last year [2] - The net profit attributable to shareholders after deducting non-recurring gains and losses was -20.68 million yuan, a significant drop of 1,858.69% year-on-year [2] - The net cash flow from operating activities was -61.54 million yuan, a decrease of 149.14% compared to the previous year [2] Historical Financial Data - From 2021 to 2024, the company's operating revenue was 1.11 billion yuan, 1.20 billion yuan, 1.22 billion yuan, and 1.12 billion yuan respectively [2] - The net profit attributable to shareholders for the same years was 109 million yuan, 107 million yuan, 40.32 million yuan, and 10.15 million yuan [2] - The net profit after deducting non-recurring gains and losses for the years was 102 million yuan, 85.30 million yuan, 12.29 million yuan, and -1.51 million yuan [2] Stock Market Performance - The company was listed on the Shenzhen Stock Exchange's ChiNext on December 28, 2021, with an initial public offering of 21.67 million shares at a price of 86.06 yuan per share [3] - The stock reached a peak price of 136 yuan on the second day of trading but has since experienced a decline, currently trading below the initial offering price [4] - The total funds raised from the IPO amounted to 1.865 billion yuan, with a net amount of 1.596 billion yuan after deducting issuance costs [4] Use of IPO Proceeds - The company planned to use the raised funds for online marketing network and information technology construction, offline marketing and service network upgrades, research and development center construction, and to supplement working capital [4]

Group 1: Company Overview - The company, Shanghai Youningwei Biotechnology Co., Ltd., reported a gross margin of approximately 50% for its proprietary brands, with a revenue growth of over 20% year-on-year in the first half of 2025 [1] - The revenue share of proprietary brands is expected to continue increasing as the company invests more in sales resources and expands its product pipeline [1] Group 2: Profitability and Sales Strategy - The gross margin for agency business is facing short-term downward pressure, but long-term prospects suggest a rationalization of margins with potential for rebound as the industry evolves [1] - The company maintains a direct sales model, which involves significant barriers such as marketing team management, high direct sales costs, and pressure on accounts receivable [1] Group 3: Market Position and Client Services - The company has developed a comprehensive service system that supports clients throughout the sales process, including product selection, training, technical support, and after-sales service [2] - The client base primarily consists of research institutions, which leads to higher accounts receivable due to reimbursement payment structures; however, the company manages this risk through effective accounts receivable control [2] Group 4: Future Plans and Market Strategy - The company plans to enhance its product offerings and expand both proprietary and third-party brands to meet diverse customer needs [2] - A share repurchase plan was initiated in 2024, with a total of 25,987,076 shares repurchased for employee stock ownership plans [2] - The company aims to leverage its 20 years of experience in life sciences to provide integrated solutions that enhance sales efficiency and customer loyalty [2]

Group 1 - The core viewpoint of the news is that You Ning Wei's stock performance and financial metrics indicate a challenging period, with a decline in revenue and net profit, alongside significant financing activity [1][2]. - As of September 15, You Ning Wei's stock price decreased by 0.41%, with a trading volume of 22.94 million yuan. The financing buy-in amount was 2.10 million yuan, while the financing repayment was 2.96 million yuan, resulting in a net financing outflow of 0.86 million yuan [1]. - The total margin trading balance for You Ning Wei reached 59.21 million yuan, accounting for 2.16% of its market capitalization, indicating a relatively high level compared to the past year [1]. Group 2 - As of June 30, You Ning Wei had 11,400 shareholders, an increase of 5.02% from the previous period, with an average of 4,994 circulating shares per shareholder, up by 31.33% [2]. - For the first half of 2025, You Ning Wei reported a revenue of 505 million yuan, a year-on-year decrease of 8.63%, and a net profit attributable to shareholders of -13.38 million yuan, a decline of 188.64% [2]. - Since its A-share listing, You Ning Wei has distributed a total of 182 million yuan in dividends, with 138 million yuan distributed over the past three years [3].

Group 1 - The company Shanghai Youningwei Biotechnology Co., Ltd. will participate in the 2025 Shanghai Listed Companies Collective Reception Day and Mid-Year Performance Briefing [1][2] - The event will be held online on September 19, 2025, from 15:00 to 17:00, allowing investors to engage with the company's management [2] - Key company representatives, including the chairman and general manager, independent directors, and the financial director, will address investor concerns regarding the company's half-year performance, governance, and strategic development [2] Group 2 - Investors can submit questions for discussion until 14:00 on September 19, 2025, through a designated webpage [2] - The company aims to enhance communication with investors and ensure that the discussion is relevant to their interests [2][3]

本次活动将采用网络远程的方式举行，投资者可登录 "全景路演"网站 (http://rs.p5w.net)；或关注微信公众号(名称:全景财经);或下载全景路演 APP，参 与本次互动交流。 活动时间为 2025 年 9 月 19 日(周五)15:00-17:00。届时公司董事长兼总经理 冷兆武先生，独立董事石磊先生、独立董事蔡鸿亮先生、独立董事金宇超先生、 董事会秘书祁艳芳女士和财务总监唐敏女士，将在线就公司 2025 半年度业绩、 公司治理、发展战略、经营状况等投资者关心的问题，与投资者进行沟通与交流， 欢迎广大投资者踊跃参与！ 为充分尊重投资者，提升交流的针对性，投资者可于 2025 年 9 月 19 日（周 五）14：00 前访问 http://ir.p5w.net/zj/进入问题征集专题页面。公司将在本次集体 接待日上，对投资者普遍关注的问题进行回答。 证券代码：301166 证券简称：优宁维 公告编号：2025-075 上海优宁维生物科技股份有限公司 关于参加 2025 年上海辖区上市公司集体接待日暨 中报业绩说明会活动的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、 ...

Group 1 - The company Shanghai Youningwei Biotechnology Co., Ltd. has signed an agreement to acquire a 15 million RMB stake in the Shanghai Hongsheng Houde Private Equity Fund Partnership, becoming a limited partner with a 2.6283% share of the total capital contribution [2][3] - The Hongsheng Houde fund has completed the necessary business registration changes and received a registration notice from the Shanghai Municipal Market Supervision Administration [3] - The fund was established on March 15, 2023, with a total capital contribution of 570.71 million RMB, and its main business activities include private equity investment and asset management [3][5] Group 2 - The company will continue to monitor the progress of the partnership and fulfill its information disclosure obligations in accordance with relevant laws and regulations [3]

Group 1 - The company, You Ning Wei, announced on September 4 that it signed a fund share transfer agreement with Shanghai Rui Ang Gene Technology Co., Ltd. and Shanghai Hongsheng Junhao Equity Investment Fund Management Co., Ltd. on August 18, 2025 [2] - The agreement involves the acquisition of a 15 million yuan stake in the Hongsheng Houde Private Investment Fund Partnership, making the company one of the limited partners in the fund [2] - After the transfer, the company's subscribed amount will account for 2.6283% of the total subscribed capital of the partnership [2]

Investment Overview - Shanghai Youningwei Biotechnology Co., Ltd. signed a fund share transfer agreement on August 18, 2025, to acquire a property share of 15 million RMB from Shanghai Ruian Gene Technology Co., Ltd. [1] - After the transfer, the company holds a 2.6283% stake in the Hongsheng Houde Private Investment Fund Partnership [1] Investment Progress - The Hongsheng Houde Private Investment Fund has completed the necessary business registration changes and received a registration notice from the Shanghai Municipal Market Supervision Administration [1] - The fund's basic registration information includes a total contribution amount of 570.71 million RMB and was established on March 15, 2023 [1] Other Information - The company will continue to monitor the partnership's progress and fulfill its information disclosure obligations in accordance with relevant laws and regulations [1]

本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 一、对外投资情况概述 上海优宁维生物科技股份有限公司（以下简称"公司"）于2025年8月18日与 上海睿昂基因科技股份有限公司（以下简称"睿昂基因"）、上海弘盛君浩股权 投资基金管理有限公司共同签署了《基金份额转让协议》，同意受让睿昂基因持 有的上海弘盛厚德私募投资基金合伙企业（有限合伙）（以下简称"弘盛厚德" 或"合伙企业"）1,500万元财产份额。本次转让完成后，公司成为弘盛厚德有限 合伙人之一，投资后公司认缴额占合伙企业总认缴额的2.6283%。具体内容详见 披露于巨潮咨询网（http://www.cninfo.com.cn）的《关于受让投资基金份额暨对 外投资的公告》（公告编号：2025-064）。 二、对外投资进展情况 近日，弘盛厚德已完成相关工商变更登记手续，并取得上海市市场监督管理 局下发的《登记通知书》。本次工商变更登记后，弘盛厚德的基本登记信息如下： 证券代码：301166 证券简称：优宁维 公告编号：2025-074 上海优宁维生物科技股份有限公司 关于受让投资基金份额暨对外投资的进展公告 主 ...

Group 1 - The company announced that as of August 31, 2025, it has repurchased a total of 0 shares through a dedicated securities account for share buybacks, representing 0% of the total share capital [1] - The company has not yet implemented the current share buyback plan [1] - The share repurchase plan complies with relevant laws, regulations, and the company's share buyback scheme [1]